MDAI vs. LUCD, OBIO, AVR, INFU, KRMD, SKIN, MGRM, ICAD, NSPR, and MBOT
Should you be buying Spectral AI stock or one of its competitors? The main competitors of Spectral AI include Lucid Diagnostics (LUCD), Orchestra BioMed (OBIO), Anteris Technologies Global (AVR), InfuSystem (INFU), KORU Medical Systems (KRMD), Beauty Health (SKIN), Monogram Orthopaedics (MGRM), iCAD (ICAD), InspireMD (NSPR), and Microbot Medical (MBOT). These companies are all part of the "medical equipment" industry.
Spectral AI vs.
Spectral AI (NASDAQ:MDAI) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.
In the previous week, Lucid Diagnostics had 7 more articles in the media than Spectral AI. MarketBeat recorded 7 mentions for Lucid Diagnostics and 0 mentions for Spectral AI. Lucid Diagnostics' average media sentiment score of 0.68 beat Spectral AI's score of 0.00 indicating that Lucid Diagnostics is being referred to more favorably in the news media.
Spectral AI has a net margin of -40.78% compared to Lucid Diagnostics' net margin of -1,069.87%.
67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 56.7% of Spectral AI shares are owned by company insiders. Comparatively, 8.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Lucid Diagnostics received 33 more outperform votes than Spectral AI when rated by MarketBeat users. However, 100.00% of users gave Spectral AI an outperform vote while only 68.97% of users gave Lucid Diagnostics an outperform vote.
Spectral AI has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.
Spectral AI currently has a consensus price target of $4.75, suggesting a potential upside of 274.02%. Lucid Diagnostics has a consensus price target of $3.50, suggesting a potential upside of 163.16%. Given Spectral AI's stronger consensus rating and higher probable upside, equities analysts plainly believe Spectral AI is more favorable than Lucid Diagnostics.
Spectral AI has higher revenue and earnings than Lucid Diagnostics. Spectral AI is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Spectral AI beats Lucid Diagnostics on 9 of the 17 factors compared between the two stocks.
Get Spectral AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spectral AI Competitors List
Related Companies and Tools
This page (NASDAQ:MDAI) was last updated on 4/25/2025 by MarketBeat.com Staff
Buy MDAI Stock Free MDAI Stock Alerts